Eli Lilly (LLY) stock is trading at record highs after the pharmaceutical company reached a deal with the White House to ...
Prescriptions for GLP-1 receptor agonists in cancer patients have increased despite lack of clinical guidance. The overall ...
GLP-1 RAs, particularly semaglutide and tirzepatide, outperform older medications in achieving significant weight loss in adults with and without type 2 diabetes. Semaglutide and tirzepatide met ...
ObesityWeek 2025, held in Atlanta from November 4-7, showcased unprecedented clinical data that signals a fundamental shift in the obesity treatment landscape. The most striking breakthrough at ...
Novo Nordisk remains a dominant business with a strong pipeline, and current multiples are low enough to justify a buy. Read my latest analysis of NVO stock.
2don MSN
Can AI Drive Peloton's Comeback?
Detailed price information for American Express Company (AXP-N) from The Globe and Mail including charting and trades.
Investor's Business Daily on MSN
The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things.
Makers of weight-loss drugs saw their stocks surge in 2024, but no more. Now Trump's price deal adds new questions. Is the ...
24/7 Wall St. on MSN
Viking Therapeutics Could Be Pharma’s Next Big Buyout Target
Quick Read GLP-1 market growth is fueling Viking Therapeutics‘ (VKTX) momentum with VK2735 in Phase 3 and VK2809’s NASH success. Viking is advancing dual therapies amid a $150 billion obesity ...
Explore Zepbound's "Changing the Threads" exhibit, which is redefining the stigma of obesity through powerful stories and ...
Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback